Q-omics provides the consensus-scored XKR9 profile across patient tissues and cancer cell-line models. XKR9 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, XKR9 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, XKR9 RNA expression shows 17,711 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where XKR9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XKR9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XKR9 survival associations across molecular data types. XKR9 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XKR9 RNA expression–survival associations across cancer types. High XKR9 expression shows unfavorable associations in KICH, COAD, UCEC and OV, but favorable associations in UCS and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for XKR9 RNA expression.
This table summarizes XKR9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for XKR9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XKR9 shows higher tumor expression in HNSC, LUAD, KIRC, KIRP, STAD and BRCA. The HNSC box plot shows higher XKR9 RNA expression in tumor versus normal tissue (log2 FC = +1.418, t-test p < 0.001).
This table shows molecular features associated with XKR9 in patient tissues and cancer cell lines. In patient samples, XKR9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, XKR9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
